CONTROLE ET MODULATION DE LA FONCTION DE LYMPHOCYTES T A RECEPTEUR D'ANTIGENE CHIMERIQUE GENETIQUEMENT MODIFIES AVEC DU DASATINIB ET D'AUTRES INHIBITEURS DE TYROSINE KINASE
The invention relates to the immunomodulatory features of dasatinib and other tyrosine kinase inhibitors towards genetically modified immune cells. The invention encompasses the indication of dasatinib and other tyrosine kinase inhibitors as an immune cell inhibitor as well as an enhancer of immune cells depending on the dosing and schedule of treatment, the administration routes, the susceptible receptor variants and the treatable cell types which can be used for immunotherapy.
